Repeated Cannabis Dosing Produced Cognitive Assessment Peaks and Valleys
In a repeated-dose vaporized-cannabis trial, digit-symbol performance differed from placebo at some assessments but not at the intervening ones. The dosing schedule was part of the time-course interpretation.
The protocol included a second administration
The review describes a neuropathic-pain trial with an initial inhalation session and a later additional session. Testing was repeated across those periods. These observations cannot be interpreted as the uninterrupted decline after one isolated dose.
Significant findings were not continuous
Both active THC conditions performed worse than placebo on the Digit Symbol Test at assessments associated with the dosing sessions. Other assessments did not show significant differences. A summary stating either that every postdose test was affected or that the task was uniformly unchanged would omit part of the pattern.
A null between assessments is not continuous monitoring
The study observed performance at scheduled points. It did not measure every moment between them or establish an individual recovery clock. Repeated administration also complicates counting elapsed time solely from the first exposure. The useful clinical finding is that task response depended on the sampled point within a dosing sequence. Reports should identify the latest dose and testing interval, preserve the nonsignificant comparisons, and distinguish a study-average pattern from a person’s actual ability at an unobserved time.
Related analysis: the review’s broader findings and limitations.
Research cited
This analysis draws on the supplied review: Eadie and colleagues (2021). Duration of Neurocognitive Impairment With Medical Cannabis Use: A Scoping Review. Frontiers in Psychiatry.
Study discussed in that review: DOI 10.1016/j.jpain.2012.10.009.
